Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

NDA for alogliptin submitted Dec. 27, Takeda tells “The Pink Sheet” DAILY, giving the drug an expected Oct. 27, 2008, PDUFA date with standard review.